AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 116 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $16,341,531 | +19.6% | 967,527 | 0.0% | 2.53% | +19.0% |
| Q4 2023 | $13,661,481 | +37.1% | 967,527 | 0.0% | 2.12% | -30.4% |
| Q3 2023 | $9,965,528 | -37.5% | 967,527 | 0.0% | 3.05% | +9.0% |
| Q2 2023 | $15,944,845 | +23.5% | 967,527 | -31.4% | 2.80% | +4.9% |
| Q1 2023 | $12,910,186 | +173.4% | 1,409,409 | +113.7% | 2.67% | +162.6% |
| Q4 2022 | $4,721,368 | +42.9% | 659,409 | 0.0% | 1.02% | +31.9% |
| Q3 2022 | $3,304,000 | +105.3% | 659,409 | 0.0% | 0.77% | +79.5% |
| Q2 2022 | $1,609,000 | -64.3% | 659,409 | 0.0% | 0.43% | -62.2% |
| Q1 2022 | $4,504,000 | -15.5% | 659,409 | 0.0% | 1.13% | +9.7% |
| Q4 2021 | $5,328,000 | -1.0% | 659,409 | +20.1% | 1.03% | +22.4% |
| Q3 2021 | $5,383,000 | +45.6% | 549,250 | 0.0% | 0.84% | +85.3% |
| Q2 2021 | $3,696,000 | -25.6% | 549,250 | 0.0% | 0.46% | -50.2% |
| Q1 2021 | $4,965,000 | +71.1% | 549,250 | +26.5% | 0.92% | +213.7% |
| Q4 2020 | $2,901,000 | – | 434,250 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,673,718 | $20,949,000 | 10.15% |
| Vivo Capital, LLC | 3,575,424 | $28,389,000 | 2.57% |
| COWEN AND COMPANY, LLC | 1,517,296 | $10,767,000 | 2.47% |
| VR Adviser, LLC | 1,057,827 | $8,399,000 | 2.28% |
| RTW INVESTMENTS, LP | 4,616,570 | $36,253,000 | 1.56% |
| GENDELL JEFFREY L | 553,516 | $4,395,000 | 1.35% |
| Avoro Capital Advisors LLC | 4,365,655 | $34,663,000 | 1.17% |
| Arlington Capital Management, Inc. | 115,902 | $920,000 | 0.85% |
| Ghost Tree Capital, LLC | 350,000 | $2,779,000 | 0.74% |
| PURA VIDA INVESTMENTS, LLC | 496,660 | $3,943,000 | 0.47% |